How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

In a phase 1 study, anti-tumor responses were induced with PRT811 treatment in patients with recurrent, high-grade glioma and advanced or metastatic uveal melanoma.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

In an interview with Targeted Oncology, Narissa Nonzee, PhD, discussed a study which focused on increasing colorectal screening rates among patients in ethnic minority communities.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

In an interview with Targeted Oncology, Alexander Helfand, MD, discussed the treatment of GIST in the second-line setting, as well as later lines, including the available options, guideline recommendations, and ongoing research.

The biologics license application for lifileucel has been accepted by the FDA for patients with advanced melanoma based on positive data from the C-144-01 clinical trial.